Company profile
VIKING THERAPEUTICS, INC.
NASDAQ:VKTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VK-2809 | phase2 | — | 3 | completed, withdrawn |
| VK-0214 | phase1 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07838740 | phase1 | recruiting | 2025-11-18 | 2027-05-01 | Viking Therapeutics, Inc. | A Phase 1 Study of VK2735 in Obese Adults Without Comorbidities |
| NCT07846033 | phase1 | recruiting | 2026-07-06 | 2026-10-02 | Viking Therapeutics, Inc. | A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities |
| NCT04173065 | phase2 | completed | 2019-11-15 | 2023-05-15 | Viking Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH |
| NCT04973657 | phase1 | completed | 2021-06-22 | 2024-10-09 | Viking Therapeutics, Inc. | A Study to Assess the Pharmacodynamics of VK0214 in Male Subjects With AMN |
| NCT02578095 | phase2 | completed | 2015-10-30 | 2017-11-15 | Viking Therapeutics, Inc. | Acute Hip Fracture Study in Patients 65 Years or Greater |
FDA applications (0)
No records yet.